Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.41 USD | +5.05% | +7.98% | +10.63% |
Sales 2024 * | 21.4M 1.78B | Sales 2025 * | 89.52M 7.46B | Capitalization | 170M 14.21B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.75B | Net income 2025 * | 8M 667M | EV / Sales 2024 * | 7.96 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-5.61
x | P/E ratio 2025 * |
55.5
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.66% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | +5.05% | ||
1 week | +7.98% | ||
Current month | -20.32% | ||
1 month | -20.09% | ||
3 months | +33.58% | ||
6 months | +98.90% | ||
Current year | +10.63% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 20/13/20 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 20/13/20 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 21/23/21 |
Earl Collier
BRD | Director/Board Member | 76 | 20/13/20 |
George Dunbar
BRD | Director/Board Member | 77 | 20/13/20 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 5.41 | +5.05% | 639,212 |
25/24/25 | 5.15 | +2.18% | 388,133 |
24/24/24 | 5.04 | +4.56% | 919,728 |
23/24/23 | 4.82 | -2.43% | 478,470 |
22/24/22 | 4.94 | -1.40% | 357,005 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.63% | 170M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CAPR Stock